Assess whether to resubmit, meet, or pause the program (a16499)

SITUATION After a boxed-warning proposal from the review division, RWE protocol that may not meet regulator expectations is what 505(b)(2) development lead can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this Pharmacovigilance file.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend To resubmit, meet, from RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend To resubmit, meet, from RWE protocol that may not meet regulator expectations; Pause the program is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close to resubmit, meet, or. 4. Two facts in RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim 505(b)(2) development lead would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in RWE protocol that may not meet regulator expectations, then the action for 505(b)(2) development lead - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Missing page in RWE protocol that may not meet regulator expectations after a boxed-warning proposal from the review division, if any - Regulatory or exam hook Pharmacovigilance would cite